Generic Name
Abiraterone Acetate
Brand Names
Abiraterone, Zytiga, Akeega, YONSA, Abirtega
FDA approval date: April 28, 2011
Classification: Cytochrome P450 17A1 Inhibitor
Form: Tablet
What is Abiraterone (Abiraterone Acetate)?
Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer Metastatic high-risk castration-sensitive prostate cancer Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer . metastatic high-risk castration-sensitive prostate cancer .
Approved To Treat
Top Global Experts
There are no experts for this drug
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment
Related Latest Advances
There is no latest advances for this treatment